Key Highlights

  • Shares fell around 12% in mid-August 2026 to about 43p with no clear regulatory trigger.
  • Full-year 2025 Revenue surged around 140% to US$11.7m, with a swing to a US$0.3m pre-tax profit.
  • Gross Margin improved to 48% from 27%, and EBITDA turned positive at US$0.7m.
  • Cash stood at just US$0.9m at year-end, with a US$500,000 Credit line largely drawn.
  • The group has won a US$3.9m Permian Basin produced-water project and a Gulf of Mexico Lease award with a super-major.

Shares in MYCELX Technologies (LSE:MYX), the AIM-quoted water-treatment and filtration specialist, fell around 12% in a single session in mid-August 2026 to about 43p, a double-digit%age drop that came with no obvious fresh trigger. The slide is jarring against a backdrop of genuine operational progress: MYCELX returned to profit in 2025 on revenue that more than doubled, and a late-July trading update pointed to a stronger second half as produced-water and PFAS projects gather pace. With the notice of the 2026 annual meeting issued on 3 August and the gathering due next month, traders appear to be weighing a thin cash cushion and lumpy project timing against a promising pipeline. The precise cause of the latest drop is unclear, making the run-up to the AGM a focal point.

What happened?

MYCELX shares dropped roughly 12% on 11 August 2026, closing near 43p, without an accompanying regulatory announcement to explain the move. The most recent company news had been the notice of the 2026 annual meeting on 3 August and a holding(s) in company disclosure on 31 July, neither of which is an obvious catalyst for a sharp fall.

The Georgia-headquartered but London-listed group cleans oil and other contaminants from water for energy and industrial customers, and has been repositioning towards higher-value produced-water treatment and PFAS remediation in the United States. On 30 July the company issued a trading update flagging a stronger second half as water-treatment projects accelerate. Against that reasonably constructive backdrop, the mid-August slide looks more like sentiment, profit-taking or the thin Liquidity typical of a small-cap than a response to hard news - and the precise trigger cannot be definitively established.

The numbers investors need to know

MYCELX's turnaround is real. For the year to 31 December 2025, reported on 7 May 2026, revenue surged around 140% to US$11.7m from US$4.9m, and the company swung to a pre-tax profit of US$0.3m from a US$2.6m loss. EBITDA turned positive at US$0.7m against a US$2.2m loss the year before, while Gross Profit rose to US$5.6m at a 48% margin, up from 27%. Basic Earnings were 1 cent a share, versus a 12-cent loss.

The Balance Sheet is the pressure point. Cash stood at just US$0.9m at the year-end, down from US$1.3m, with a US$500,000 line of credit opened in August 2025 and US$450,000 drawn. On the commercial side, the group has been awarded a US$3.9m produced-water project in the US Permian Basin, secured a PFAS mobile-treatment rental contract with the US Department of Defense in North Dakota, and in May 2026 announced a new Gulf of Mexico lease award with a super-major. At around 43p the company is valued well below the levels seen earlier in its recovery.

Why the market may be concerned

The dominant concern is cash. Finishing 2025 with US$0.9m and a largely drawn US$0.5m credit line leaves little margin for error at a company whose revenue is inherently lumpy and project-driven. MYCELX has itself acknowledged the need to manage Working Capital carefully to support growth, and commentators have questioned whether the balance sheet is robust enough to fund the ramp-up.

Revenue timing is a second issue. The Business has a history of milestone-driven revenue that can slip between quarters, and management struck a cautious note on Middle East geopolitical risk in its results. With so much of the near-term story dependent on a handful of large US contracts converting on schedule, any delay could hit both reported revenue and cash. On an Illiquid AIM line, that uncertainty can translate quickly into sharp share-price moves like the one just seen.

Why bulls may see an opportunity

Bulls point to a business that has decisively turned the corner: revenue up 140%, a return to profit and EBITDA, and gross margins expanding to 48%. The pivot towards produced water and PFAS taps two large and growing US environmental markets, and Blue-Chip counterparties - a super-major in the Gulf of Mexico and the US Department of Defense - lend the pipeline credibility.

The 30 July update pointing to a stronger second half suggests momentum is building rather than fading, and trials demonstrating 99%-plus oil recovery underpin the technology's competitive position. If the enquiry pipeline converts and the Permian and Gulf projects deliver, bulls argue the post-drop valuation could look cheap for a profitable, growing niche water-technology company - particularly if the balance sheet is strengthened.

The technology's environmental credentials also chime with tightening US regulation of PFAS - the so-called forever chemicals - and of produced-water disposal, giving MYCELX a potential regulatory tailwind that could broaden Demand well beyond its traditional oil-and-gas customer base over the medium term.

What happens next?

The immediate focus is the 2026 annual meeting, notice of which was published on 3 August 2026 and which is expected to be held in September. AGMs often come with a current-trading statement, and shareholders will look for reassurance on the cash position, the timing of US project revenue and the strength of the second-half pipeline.

Beyond the meeting, key catalysts include progress on the US$3.9m Permian produced-water project, delivery under the Gulf of Mexico lease award, expansion of the PFAS remediation work, and any move to bolster working capital. Half-year results later in the year will show whether the second-half acceleration management has flagged is translating into cash as well as revenue. Directorate changes announced in June, including the appointment of a new non-executive director, add a further watch-point on governance and strategy as the board oversees the US-focused pivot.

Outlook

MYCELX (LSE:MYX) presents a sharp contrast between improving fundamentals and a nervy share price. The 2025 results confirmed a genuine turnaround - revenue up 140%, a return to profit and expanding margins - yet the shares fell by double digits in August with no clear catalyst, underscoring how sensitive the stock is to cash and timing worries. The Investment debate comes down to whether the US produced-water and PFAS pipeline can convert quickly enough to outrun a tight balance sheet. The September annual meeting and any accompanying trading commentary should help clarify that, but until the cash question is answered, Volatility is likely to remain a feature.